Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This randomized control trial reported that patients with alopecia areata typically have lower serum Vitamin D levels, and treatment with topical vitamin D3 analogue calcipotriol led to significant hair regrowth in 71% of participants over six months.

This article discusses the diagnostic challenges of evaluating hair and scalp conditions in patients using hair dye, emphasizing how dyes can mimic different pathologies and lead to contact dermatitis.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This article reviews hair growth patterns in humans and laboratory animals, noting the random distribution of active and inactive hair follicles and differences in regional coordination among animal species, and reports no new results.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This study found significantly lower serum vitamin D concentrations in patients with alopecia areata compared to healthy controls, suggesting that vitamin D deficiency may be a risk factor for this autoimmune hair loss disease.

This case report describes how alopecia areata and Beau's lines resolved in a child following treatment for Kawasaki disease, suggesting these symptoms may be linked to the underlying autoimmune process.

This case report observed that while a 4-year-old boy with vitamin D-dependent rickets type II showed biochemical and bone improvement after vitamin D and calcium treatment, his alopecia did not improve.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

This study observed that DNA damage response (DDR) plays a key role in pressure overload-induced cardiomyocyte hypertrophy, with disruption of the ATM kinase pathway potentially modulating this hypertrophy in mice.

This study introduces diagnostic and therapeutic algorithms tailored for tailored management of alopecia areata based on patient-specific factors like age, disease severity, and quality of life.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This article reviews the use of tofacitinib for rheumatoid and psoriatic arthritis and alopecia areata, noting potential serious side effects, but reports no cases of palmoplantar pustulosis from the therapy.

This study suggests that long-term treatment with the contact sensitizer SADBE in mice may reduce leucocyte traffic in alopecia areata through impaired leucocyte extravasation.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

This study found evidence that atopic dermatitis may increase the risk of developing rheumatoid arthritis, type 1 diabetes, and alopecia areata, but not other autoimmune diseases.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

This article discusses alopecia areata incognito, highlighting its diffuse hair loss pattern and favorable response to steroid treatment, but it reports no new clinical data.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This report describes a rare scalp condition in children with features similar to tinea capitis but shows negative fungal cultures, and suggests possible slow improvement with griseofulvin in two cases.

This study found that the RapidHIT™ ID system can successfully obtain DNA profiles from single hair roots, particularly those with high nuclei counts.